Table 2. Predictors of success of liposomal amphotericin B in 41 patients with tegumentary leishmaniasis.
| Complete healing without relapse | Failure or relapse | Success of L-AmB |
p value | |||
|---|---|---|---|---|---|---|
| n = 19a | n = 22a | (%) | ||||
| Patients | ||||||
| Age | 57 [2–80] | 42 [1–86] | / | 0.58 | ||
| Immunocompromised subject | 2 (10) | 3 (14) | 40 | 0.99 | ||
| Localized cutaneous form | 14 (74) | 17 (77) | 45 | 0.99 | ||
| Mucocutaneous form | 4 (21) | 3 (14) | 57 | 0.68 | ||
| Frontline therapy with L-AmB | 15 (79) | 15 (68) | 50 | 0.44 | ||
| Country where infection was acquired | ||||||
| Old World | 15 (79) | 11 (50) | 58 | 0.05 | ||
| New World | 4 (21) | 11 (50) | 27 | 0.05 | ||
| Leishmania species | ||||||
| Viannia subgenus | 4 (21) | 10 (45) | 28 | 0.13 | ||
| L. infantum | 7 (37) | 2 (9) | 78 | 0.06 | ||
| L. major | 2 (10) | 4 (18) | 50 | 0.99 | ||
| Clinical findings | ||||||
| Number of lesions | 2 [1–30] | 2 [1–8] | / | 0.84 | ||
| Treatment | ||||||
| Cumulative dose of L-AmB (mg/kg) | 20 [6–40] | 20 [16–56] | / | 0.73 | ||
L-AmB, liposomal amphotericin B. Data are represented as n (%) or median [range] unless otherwise indicated.
aTwo patients with improvement at first control visit (before day 90) but no subsequent follow-up were excluded from the analysis.